Strides Pharma Science Limited, headquartered in Bengaluru, India, is a prominent pharmaceutical company specialising in the manufacturing of pharmaceutical products, over-the-counter (OTC) drugs, and nutraceuticals. Its diverse product portfolio includes soft gel capsules, hard-gel capsules, tablets, as well as dry and wet injectables.

Strides Pharma Unit Gets USFDA Nod

On January 20, 2025, Strides Pharma announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Ltd., Singapore, has received a coveted approval from the United States Food and Drug Administration (USFDA) for its Acetaminophen and Ibuprofen tablets (125 mg/250 mg, OTC).

The company confirmed that this product is bioequivalent to the reference listed drug, Advil Dual Action with Acetaminophen (125 mg/250 mg, OTC), marketed by Haleon US Holdings LLC.

Statement From Strides Pharma Company

This milestone further enriches Strides Pharma’s portfolio of OTC products, the company stated. “By introducing a dual-action pain relief option, we aspire to cater to a wider patient demographic, delivering effective and accessible solutions for pain management,” said a company representative.

The tablets will be manufactured at the company’s state-of-the-art flagship facility in KRSG, Bengaluru.

Details About NSAID

The combination of Acetaminophen and Ibuprofen offers relief from a variety of ailments, including headaches, dental pain, menstrual cramps, muscle aches, and arthritis. 

“Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), works synergistically in this formulation by inhibiting the body’s production of natural substances responsible for inflammation. This action effectively reduces swelling, pain, and fever,” the company explained.

Strides Pharma Q2 FY25 Results

Strides Pharma reported a strong turnaround in Q2 FY25, posting a net profit of ₹93.7 crore compared to a net loss of ₹149.45 crore in the same period last year. 

Revenue from operations grew 20% YoY to ₹1,201.11 crore, driven by new product launches and a 26.2% surge in US revenues to $75 million. EBITDA rose 31% to ₹235.8 crore, with margins improving to 19.6% from 17.5% a year ago.

Share Price Performance 

At 10:22 AM today, Strides Pharma Science Limited shares traded at ₹586.00 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Jupiter Life Line Hospitals Limited is a premier multi-speciality tertiary and quaternary healthcare provider operating under the esteemed “Jupiter” brand in India. Established in 2007, the organisation manages three state-of-the-art hospitals located in Thane, Pune, and Indore, collectively offering an operational bed capacity of 950 as of September 2024.

Acquired Land For ₹400 Crores

Jupiter Life Line Hospitals Ltd. has acquired a prime parcel of land spanning approximately 8,433 square metres in Ghodbundar, Mira Road, Thane district. The forthcoming hospital, designed to cater to underserved regions such as Dahisar, Mira Bhayandar, and the Vasai Virar Municipal areas, underscores the company’s vision of accessible and quality healthcare.

About Jupiter Life Line Hospitals Ltd 

As of January 1, 2025, the company operates an impressive 1,061 beds, maintaining a commendable 67.2% occupancy rate as of September 30, 2024. The proposed facility is anticipated to add a further 300 beds to its capacity, with completion targeted within approximately four years.

This ambitious project entails a capital investment of ₹400 crores, to be primarily funded through internal accruals. The ultimate financing structure will be subject to the Board of Directors’ discretion, adhering to regulatory approvals.

Jupiter Life Line Hospitals Q2 FY25 Results

Jupiter Life Line Hospitals Ltd. reported outstanding financial results for Q2 FY25, with consolidated net profit soaring 52.91% YoY to ₹51.50 crores and revenue from operations rising 22.57% to ₹322.57 crores. 

Profit before tax surged 66.55% to ₹68.9 crores, while EBITDA grew 23.5% to ₹76.6 crores with a robust 19.2% margin. For H1 FY25, total income increased 20.5% to ₹612.8 crores, EBITDA expanded 22.3% to ₹141.9 crores, and PAT rose 9.6% to ₹96.1 crores.

Share Price Performance

At 10:20 AM today, Jupiter Life Line Hospitals Ltd. shares traded at ₹1,530.00 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Indian Oil Corporation (IOC) has issued its first tender for sour crude imports since March 2022. This comes in light of fresh US sanctions on Russian oil producers and tankers, prompting refiners to explore alternative supply options. Alongside its sour crude tender, IOC has floated a separate tender for sweet crude oil, seeking supplies for loading between February 16 and March 15, 2024. 

Indian Oil Corporation (IOC) Ltd stock was at ₹130.39 today, on January 20, at 3:24 PM, up 1.81% for the day but down 22.47% over 6 months and 6.16% over the past year.

Impact of US Sanctions

The new sanctions, targeting Russian producers Gazprom Neft and Surgutneftegaz and 180 tankers, are expected to impact the flow of Russian oil to India. These measures, effective from March 12, 2024, after a wind-down period, could end discounts on Russian oil. 

The sanctions also pose challenges for Indian refiners, as transactions involving sanctioned tankers may attract secondary sanctions, complicating dollar payments and dealings with US entities.

Indian Oil Corporation’s (IOC) Purchases

IOC has procured 7 million barrels of crude oil from the spot market, including supplies from the Middle East and Africa. This includes a purchase of Abu Dhabi’s Murban crude, acquired at a premium of approximately $5 per barrel above Dubai quotes. Other purchases include 1 million barrels each of Nigeria’s Agbami and Akpo crude, Gabon’s Rabi Light, and Angola’s Nemba crude.

Rising Crude Premiums and Tanker Rates

Spot premiums for Middle Eastern crude reached their highest levels in over 2 years, driven by demand from China and India. Meanwhile, tanker rates have surged, further increasing procurement costs. Indian refiners, heavily reliant on Russian oil, now face challenges in sourcing affordable alternatives amid rising costs.

Market Adjustments by Indian Refiners

With reduced Russian oil supplies, IOC and other Indian refiners are increasingly turning to the Middle Eastern spot market. This shift shows the broader impact of geopolitical developments on global energy markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Gland Pharma, a leading injectable-focused pharmaceutical company, operates across 60 countries, including the U.S., Europe, Canada, Australia, and India. Its diverse portfolio features vials, ampoules, pre-filled syringes, lyophilised vials, dry powders, infusions, and specialised oncology and ophthalmology solutions, showcasing its global impact and innovation in healthcare.

Got EIR from USFDA

Gland Pharma recently announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pashamylaram facility in Hyderabad. 

The issuance of the EIR signifies the successful closure of the inspection, which was conducted between 25th July and 2nd August 2024. During this period, the USFDA reviewed the site’s adherence to Good Manufacturing Practices (GMP) and issued three procedural Form 483 observations.

Gland Pharma Q2 FY25 Results

Gland Pharma reported a 15.7% year-on-year decline in net profit, amounting to ₹163.5 crore for Q2 FY25, attributed largely to diminished European sales and operational hurdles at its French subsidiary, Cenexi. However, the company witnessed a modest 2.4% growth in revenue from operations, reaching ₹1,405.83 crore. This growth was propelled by a 3% uptick in U.S. sales and an impressive 45% surge in other international markets.

EBITDA for the quarter contracted by 8% to ₹297.06 crore, with margins narrowing to 21.1% from 23.6% in the prior year. Research and development (R&D) expenditure totalled ₹49.3 crore, accounting for 4.6% of revenue. During the quarter, Gland Pharma filed 7 new Abbreviated New Drug Applications (ANDAs) and secured eight approvals, underscoring its commitment to innovation.

Share Price Performance 

At 3:30 PM today, Gland Pharma share price traded at ₹1,670.00 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Dixon Technologies (India) Limited, founded in 1993 by Sunil Vachani and headquartered in Noida, Uttar Pradesh, is a leading Indian multinational electronics manufacturing services (EMS) company. 

Dixon Acquired the land and Assets of KHY Electronics

On January 20, 2025, Dixon Technologies share price surged nearly 2% following the company’s announcement of plans to acquire the land and assets of KHY Electronics India.

In a regulatory filing, Dixon disclosed that its subsidiary, IsmartU India Private Limited (IIPL), has entered into a binding Memorandum of Understanding (MoU) with KHY Electronics India. Through this agreement, the subsidiary will acquire machinery, land, buildings, and other tangible assets of KHY for a total consideration of ₹133 crore.

Dixon Technologies Q2 FY25 Results

Dixon Technologies showcased a stellar performance in Q2 FY25, with net profit skyrocketing by 265% year-on-year to ₹412 crore, boosted by a ₹209.6 crore one-off gain from the divestment of its stake in a joint venture. Excluding this exceptional item, the adjusted net profit climbed 109% to ₹236 crore, while revenue soared by a remarkable 120% to ₹18,116 crore, propelled by a 235% surge in its mobile segment, which contributed an impressive 82% to the top line.

Although the EBITDA margin stood at 3.7%, slightly trailing expectations due to the higher contribution of the lower-margin mobile business, the company exuded confidence in its growth trajectory by revising its FY25 revenue guidance upwards to ₹40,000 crore. This comes despite a 10% dip in share prices, underscoring its robust strategic outlook and sustained momentum.

Share Price Performance 

At 3:24 PM today, Dixon Technologies (India) share price traded at ₹17,540.00 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Dalmia Bharat has firmly established itself as one of India’s most esteemed cement manufacturers, playing a pivotal role in nation-building through significant capacity expansion, unwavering commitment to superior quality standards, and innovative value-added products.

Signed Share Subscription Agreement

Dalmia Bharat’s wholly-owned subsidiary, Dalmia Cement (Bharat) Limited (DCBL), signed a Share Subscription and Shareholders Agreement (SSSHA) on January 17, 2025. 

The agreement outlines DCBL’s acquisition of a 26% equity stake in Solis Urja Energy, amounting to 17,50,000 equity shares valued at ₹1.75 crore, to be executed in multiple tranches. This move facilitates the procurement of solar power as a captive consumer for a capacity of up to 7.0 MWp in Andhra Pradesh.

The transaction is subject to customary conditions precedent and is expected to conclude within six months. This strategic acquisition underscores Dalmia Bharat’s commitment to sustainability, aligning with the group’s ambitious RE100 target by 2030 and its vision to achieve carbon negativity by 2040. 

Q2 FY25 Results

In its Q2 FY25 results, Dalmia Bharat reported a consolidated net profit of ₹49 crore, reflecting a notable 60.16% decline from ₹123 crore in the same quarter last year. 

Revenue from operations also witnessed a slight dip, decreasing by 2.09% to ₹3,087 crore compared to ₹3,153 crore in the same period of the previous fiscal year. However, despite these challenges, the company demonstrated robust operational performance, with sales volumes increasing by 14.1% to 6.7 million tonnes. The board declared an interim dividend of ₹4 per share, with a record date of October 26, 2024.

Share Price Performance

As of 2:49 PM today, Dalmia Bharat Ltd shares were trading at ₹1,752.25 on the NSE, reflecting a rise of over 1%. The BSE-listed ‘A’ group stock, with a face value of ₹2, recorded a 52-week high of ₹2,428.85 on 14th December 2023 and a 52-week low of ₹1,664.20 on 4th June 2024.

Over the past week, the stock has traded within a range of ₹1,928.95 to ₹1,814.10. The company’s current market capitalisation stands at an impressive ₹34,381.23 crore.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.